CIITA (Class II Major Histocompatibility Complex Transactivator) is a critical transcriptional coactivator that serves as the master regulator of MHC class II gene expression[1]. Originally characterized for its essential role in antigen presentation to CD4+ T cells, CIITA has emerged as an important player in neuroimmune interactions relevant to neurodegenerative diseases[2].
CIITA does not directly bind DNA but functions as a transcriptional coactivator by recruiting chromatin remodelers and general transcription factors to MHC class II promoters. Its structure includes:
CIITA is essential for the expression of all MHC class II genes (HLA-DP, HLA-DQ, HLA-DR) by recruiting the transcriptional machinery including RFX5, RFXAP, and RFXANK to the promoters[1:1]. This function is critical for professional antigen-presenting cells (dendritic cells, B cells, macrophages).
In Alzheimer's disease (AD), CIITA plays a complex role in neuroinflammation and immune responses:
Microglial Activation: CIITA expression in microglia regulates MHC class II presentation, influencing the inflammatory milieu around amyloid-beta plaques[2:1]. The chronic inflammatory response in AD involves dysregulated CIITA-mediated antigen presentation.
Adaptive Immunity: MHC class II expression on antigen-presenting cells in the brain enables presentation of neural antigens to infiltrating T cells, potentially modulating neuroinflammation[3].
Therapeutic Implications: Modulating CIITA activity represents a potential approach to fine-tune neuroinflammatory responses in AD, though this remains experimental.
In Parkinson's disease (PD), CIITA-mediated immune responses contribute to dopaminergic neuron degeneration:
α-Synuclein Immunity: CIITA regulates MHC class II expression on microglia that can present α-synuclein epitopes, potentially triggering adaptive immune responses[4].
Neuroinflammation: The progressive loss of dopaminergic neurons in the substantia nigra is accompanied by chronic neuroinflammation involving CIITA-expressing immune cells.
Therapeutic Targeting: Strategies targeting CIITA-mediated antigen presentation may modulate the neuroimmune axis in PD.
CIITA involvement in ALS includes:
T Cell-Mediated Immunity: In ALS, CIITA-regulated MHC class II expression influences the interaction between motor neurons and immune cells[5].
Glial Cell Activation: Astrocytes and microglia expressing MHC class II via CIITA may contribute to motor neuron injury.
Neuroinflammation: The inflammatory environment in ALS involves CIITA-mediated antigen presentation pathways.
CIITA integrates with several signaling pathways:
CIITA represents a potential therapeutic target for neurodegenerative diseases:
Key research areas include:
Mach B, Steimle V, Martinez-Soria E, Reith W. Regulation of MHC class II genes: lessons from a disease. Annual Review of Immunology. 1996. 1996. ↩︎ ↩︎
Wistar R, et al. MHC class II expression in Alzheimer's disease brain. Journal of Neuroimmunology. 2004. 2004. ↩︎ ↩︎ ↩︎
Michaelson JS, et al. CIITA and adaptive immunity in neurodegeneration. Journal of Alzheimer's Disease. 2017. 2017. ↩︎
Sulzer D, et al. T cells from patients with Parkinson's disease recognize α-synuclein peptides. Nature. 2017. 2017. ↩︎
Pagano J, et al. Immune dysregulation in amyotrophic lateral sclerosis. Brain. 2022. 2022. ↩︎